Apalulizumab

N/A

Report date: 2025/12/31 20:01:55

Base Information

Drug NameApalulizumab

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-PD-1Anti-CTLA4

TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesShanghai Rui Jin Hospital

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Rui Jin Hospital

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A